Is Royalty Pharma plc overvalued?

Royalty Pharma plc (RPRX) looks overvalued — trading about 52% above its fair value.

Overvalued

Price

$56.23

Fair value

$26.88

Current P/E

31.2

Normal P/E

14.9

Market cap

$24.19B

Dividend yield

2.3%

Return on equity

11.9%

Sector

Healthcare

Fair value compares RPRX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 28 Jun 2026.

Related stocks